

Community Health Choice (HMO D-SNP) Medicare Part D Plan

Step Therapy Criteria
Last Updated 5/1/2026

Products Affected

CONEXXENCE 60MG/ML SYRINGE

Details

Criteria Step Therapy requires trial of one formulary bisphosphonate. Step not required for the treatment of: 1) Bone loss in men receiving androgen deprivation therapy for prostate cancer or 2) Bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer.

Products Affected

febuxostat 40mg tab

Details

Criteria	Step Therapy requires trial of generic allopurinol.
----------	---

Products Affected

febuxostat 80mg tab

Details

Criteria	Step Therapy requires trial of generic allopurinol.
----------	---

Products Affected

JUBBONTI 60MG/ML SYRINGE

Details

Criteria	Step Therapy requires trial of one formulary bisphosphonate. Step not required for the treatment of: 1) Bone loss in men receiving androgen deprivation therapy for prostate cancer or 2) Bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer.
----------	--

Products Affected

TRINTELLIX 10MG TAB

Details

Criteria	Step therapy requires trial of one of the following generic antidepressants: escitalopram, sertraline, fluoxetine, citalopram, paroxetine, fluvoxamine, bupropion, venlafaxine, desvenlafaxine, or duloxetine.
----------	--

Products Affected

TRINTELLIX 20MG TAB

Details

Criteria	Step therapy requires trial of one of the following generic antidepressants: escitalopram, sertraline, fluoxetine, citalopram, paroxetine, fluvoxamine, bupropion, venlafaxine, desvenlafaxine, or duloxetine.
----------	--

Products Affected

TRINTELLIX 5MG TAB

Details

Criteria	Step therapy requires trial of one of the following generic antidepressants: escitalopram, sertraline, fluoxetine, citalopram, paroxetine, fluvoxamine, bupropion, venlafaxine, desvenlafaxine, or duloxetine.
----------	--